Barclays lifts target for Elevance Health stock to USD 469

Published on 10/13/2026 at 16:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 21, 2026. Elevance Health stock costs EUR 380.10 on October 13, 2026, up 0.86 percent on Nasdaq.

Target, results and valuation

Barclays lifted its Elevance Health price target to USD 469 on October 7, 2026.
Elevance Health will report third-quarter 2026 results on October 21, 2026.
Elevance Health stock costs EUR 380.10 at Lang & Schwarz on October 13, 2026 at 3:59 p.m. CEST, plus 0.86 percent on Nasdaq versus October 12, 2026.
The price-to-earnings ratio was 18.96 and market capitalization was USD 92.3 billion on October 13, 2026.

Draufsicht-Arrangement mit Aktienzertifikat, ISIN-Karte US2855211023 und Stethoskop — Elevance Health US2855211023 Flatlay mit Aktienzertifikat ISIN-Karte Stethoskop und medizinischen Utensilien auf Marmor, Illustration mit AI erstellt.

Barclays raised its Elevance Health price target from USD 457 to USD 469 on October 7, 2026, while maintaining an Overweight rating, according to Markets Insider. That target stood 10.16 percent above the Nasdaq price of USD 425.71 on October 13, 2026. Elevance Health stock was at EUR 380.10 at Lang & Schwarz on October 13, 2026 at 3:59 p.m. CEST, while the Nasdaq quote was plus 0.86 percent versus the October 12, 2026 prior close.

Results arrive October 21

Elevance Health will release third-quarter 2026 financial results on October 21, 2026, at 6:00 a.m. EDT, according to Business Wire. Management is scheduled to discuss the results and outlook during a conference call at 8:30 a.m. EDT that day, giving the calendar event a clear place in the near-term trading schedule.

Stock remains below yearly high

The Nasdaq price of USD 425.71 on October 13, 2026 stood below the 52-week high of USD 436.24 and above the 52-week low of USD 274.84. The same quote showed volume of 189,455 shares against an average volume of 1,200,384 shares, so the session figure was 84.22 percent below that average.

For investors, the distance to the yearly high is narrower than the gap to the yearly low. The USD 469 Barclays target also sits above the current Nasdaq price, but it is an analyst assessment rather than a company forecast.

Valuation before the report

Elevance Health had a market capitalization of USD 92.3 billion and a price-to-earnings ratio of 18.96 on October 13, 2026. The current valuation gives the October 21 reporting date a concrete reference point, especially because the upcoming release will update earnings expectations for the remainder of 2026.

Elevance Health describes its business as an integrated health company focused on improving health outcomes, lowering costs and simplifying experiences. That model spans health coverage and related services, while the upcoming results will provide the next dated operating check.

Price and investor reference

At Lang & Schwarz, Elevance Health stock was trading at EUR 380.10 on October 13, 2026 at 3:59 p.m. CEST. The Nasdaq quote was USD 425.71, plus 0.86 percent versus USD 422.09 on October 12, 2026.

The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.